Lynozyfic: A New Hope in Blood Cancer Treatment
The Clinical Need for Innovation One of the key challenges in treating multiple myeloma is its tendency to return even after several lines of therapy. It is estimated that in the U.S., nearly 8,000 patients progress after receiving three prior treatments, and about 4,000 relapse even after four stages of therapy. These patients often face limited options and poor prognoses. The urgency for more effective treatment options led the FDA to expedite the approval process for Lynozyfic based on promising early trial data.
